engleski

Safety of relaxing coagulation control by anti- tissue factor pathway inhibitor in hemophilia patients: Impact of tissue distribution of tissue factor

In patients with hemophilia the beneficial pro- hemostatic effects of inhibiting tissue factor pathway inhibitor (TFPI) in tissues where tissue factor (TF) expression is low such as the joints could be compromised by the prothrombotic effects of TFPI inhibition in tissues where TF is higher constitutively or upon stimulation. The concomitant treatment with TFPI inhibitors and rFVIIa, aPCC or FVIII/FIX concentrates should be cautiously evaluated, due to their synergistic procoagulant effect.

adverse effects, hemophilia, tissue factor, tissue factor pathway inhibitor, thrombosis,

nije evidentirano